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Abstract
Dengue virus (DENV) is a major public health threat worldwide. A key element in protection
from dengue fever is the neutralising antibody response. Anti-dengue IgG purified from
DENV-2 infected human sera showed reactivity against several peptides when evaluated
by ELISA and epitope extraction techniques. A multi-step computational approach pre-
dicted six antigenic regions within the E protein of DENV-2 that concur with the 6 epitopes
identified by the combined ELISA and epitope extraction approach. The selected peptides
representing B-cell epitopes were attached to a known dengue T-helper epitope and evalu-
ated for their vaccine potency. Immunization of mice revealed two novel synthetic vaccine
constructs that elicited good humoral immune responses and produced cross-reactive neu-
tralising antibodies against DENV-1, 2 and 3. The findings indicate new directions for epi-
tope mapping and contribute towards the future development of multi-epitope based
synthetic peptide vaccine.
Introduction
Dengue virus (DENV) is a major public health problem especially in the tropical and subtropi-
cal regions of the world with approximately 390 million people infected annually [1]. DENV
comprises four serotypes (DENV-1, 2, 3, and 4) which belong to the Flavivirus genus of the
Flaviviridae family. The DENV genome is composed of a single, positive-stranded RNA
genome of 11 kb that codes for a large polyprotein comprising a capsid protein (C), a mem-
brane protein (M), the major envelope glycoprotein (E) and other non-structural proteins [2].
The E protein is involved in receptor binding of DENV and is the target of neutralising anti-
bodies. The E protein ectodomain consists of three structural domains referred to as domain I
(EDI), domain II (EDII), and domain III (EDIII) [3]. EDI is the central domain containing
virus-specific cross-reactive epitopes [4]. EDII contains the fusion loop and is involved in
dimerization and membrane fusion. The highly conserved fusion loop forms the epicentre of a
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series of overlapping immunodominant cross-reactive epitopes eliciting predominantly non-
or weakly neutralizing antibodies [5, 6]. EDIII is an immunoglobulin-like structure that con-
tains DENV complex cross-reactive epitopes with neutralizing antibodies to multiple serotypes
[7, 8].
Dengue infections can vary from asymptomatic or self-limiting mild flu-like illness to classi-
cal dengue fever (DF), to the more severe disease state characterized as dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS) [9]. The severe complications are reported to
be due to the pathogenic manifestations of the complex human immune responses, antibody
cross-reactivity leading to disease enhancement due to cytokines and chemokines [10, 11]. A
number of vaccine candidates are under development such as live attenuated vaccines, chime-
ric vaccines, recombinant vaccines, inactivated vaccines, virus like particles and subunit vac-
cines [1, 12]. The Sanofi Pasteur tetravalent chimeric yellow-fever dengue (CYD-TDV) vaccine
(Dengvaxia1) is the front-runner of all experimental vaccines after completing a double-
blinded, placebo-control, large phase III clinical trial in Asia (Indonesia, Malaysia, Philippines,
Thailand, Vietnam) [13] and the Latin America (Brazil, Colombia, Honduras, Mexico, Puerto
Rico) [14]. CYD-TDV was created by inserting the DENV pre-M and E genes in to the cDNA
backbone of the YF 17D vaccine, replacing the native yellow fever pre-M and E genes.
Although the overall vaccine efficacies in Asia and Latin America were reported to be 56.5%
and 64.7%, respectively, the serotype-specific vaccine efficacy in Asia was substantially lower at
50% for serotype 1 and 35% for serotype 2 [13]. Similar trend in serotype-specific vaccine effi-
cacy was also reported in the Latin American phase III clinical trial where the efficacies were
50.3% for serotype 1 and 42.3% for serotype 2 [14].
Epitope identification through the use of short synthetic peptides has drawn much attention
and a number of synthetic peptide-based approaches have identified the antigenic determi-
nants in DENV [15–18]. Computational biology has contributed to predictive pathobiology of
life threatening organisms and there are many bioinformatics tools that can be applied to pre-
dict the B and T cell epitopes [19]. A number of attempts were made to predict the B-cell epi-
topes of DENV with improvements in the accuracy of B-cell epitope prediction by designing
more appropriate algorithms such as the Hidden Markov Model (HMM) [20] and the Artificial
Neural Network (ANN) [17, 21–23].
Proteolytic footprinting methods such as the epitope extraction technique has been used to
map the epitopes of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) [24,
25]. This approach is unique in that it is able to identify the antigen bound to the antibody in
its native conformation under physiological conditions [24, 25]. The detection of the antigen is
possible in combination with matrix-assisted laser desorption (MALDI)-time of flight (TOF)
mass spectrometry for the characterization of linear and discontinuous epitopes. However, B-
cell epitope prediction using a single method is usually not sufficient to identify epitopes at a
scale greater than random and a multiple step epitope identification scheme can help to
increase the odds of identifying novel candidate epitopes. In addition, short synthetic peptides
generally do not induce good immune responses on their own and helper T-cell can be pro-
vided through co-synthesizing linear helper T-cell epitopes along with the B-cell epitopes [26].
In this study, we combined different strategies for B-cell epitope identification and evaluate
the vaccine potency of synthetic peptide based vaccine constructs in mice. A multi-step
sequence and structure based bioinformatics approach was used to predict the potential B-cell
epitope candidates. Also, an overlapping peptide library representing the entire E protein of
DENV-2 was used to screen the anti-dengue Immunoglobulin G (IgG) purified from neutralis-
ing DENV-2 polyclonal human sera. The binding profile of each peptide against the IgG was
evaluated using both ELISA and epitope extraction approach. A combination of ELISA and
epitope extraction revealed several novel linear B-cell epitopes which provide new insights for
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future development of epitope-based dengue vaccines. Selected peptides were co-synthesised
with a known T-helper epitope from dengue virus [27] and these vaccine constructs were eval-
uated in mice for their potential to elicit anti-peptide antibodies that could cross-neutralise the
dengue virus.
Materials and Methods
Ethical considerations
The study was approved by the Cairns and Hinterland Health Service District Human Research
Ethics Committee (Protocol No. HREC/10/QCH/17-646), and the Human Research Ethics
Committee of Swinburne University of Technology (SUHREC- 2010/158). Detailed explana-
tion of the study was provided and written consent to participate in the study was obtained
from volunteers. All data were handled confidentially. The protocol for animal use was
reviewed and approved by the Swinburne Animal Ethics Committee (SAEC) (Protocol No.
SAEC Project 2011/02).
Human sera
The subjects/travelers were recruited based on their previous infection history and hospital rec-
ords held at Cairns Base Hospital, Queensland, Australia. The presence of dengue antibody
was identified using PanBio dengue IgM/IgG kit (Brisbane, Australia) and the infected serotype
was determined by RT-PCR during the acute infection stage. For this study, we collected the
convalescent sera from dengue positive volunteers and stored at -20°C until further use. Focus
reduction neutralisation test (FRNT) was performed to determine the neutralising ability of
the patient sera. The sera that showed positive neutralisation against one or more DENV sero-
types were included in the study. The negative control samples did not neutralise any DENV
serotype and was negative to dengue IgG ELISA. The subjects exposed to other flaviviruses or
flavivirus vaccines were excluded based on hospital records. The FRNT titers of sera against all
4 dengue serotypes and other particulars of the subjects are provided as supplementary (S1
Table).
Cell lines, viruses and antibodies
Baby hamster kidney cells (BHK-21 clone 15) [28], Aedes albopictusmosquito cells (C6/36)
[29], dengue virus prototypes DENV-1 (Hawaii), DENV-2 New Guinea C (NGC), DENV-3
(H87) and DENV-4 (H241) were kind gifts from Professor John Aaskov, WHO collaborating
Centre for Arbovirus Reference and Research, Queensland University of Technology,
Australia.
Stocks of DENV prototype viral strains were grown using confluent monolayer of C6/36
cells. Plaque titration was performed on BHK-21 cells as previously described by Morens et al.
(1985) with modifications. Briefly, cell monolayers were prepared by seeding 24 well tissue cul-
ture plates and infected with serial ten-fold dilutions (10−1 to 10−6) of virus in RPMI-1640
(Invitrogen, MA, USA) containing 2% heat-inactivated FBS (Invitrogen, MA, USA). After 2
hours, the wells were overlaid with 1.5% w/v CMC overlay medium and incubated at 37°C with
5% CO2 for 5–6 days. The infected cells positive for the E protein of DENV were enumerated
by intracellular staining using the monoclonal antibody 4G2 (clone D1-4G2-4-15) (Chemicon,
Merck Millipore, MA, USA) which was recognized by Horseradish Peroxidase (HRP)-conju-
gated goat anti-mouse IgG (Sigma, MO, USA).
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Immunoglobulin G purification
The immunoglobulin G (IgG) fractions were purified from human sera using Protein
A-Sepharose Fast Flow affinity chromatography (Sigma-Aldrich, MO, USA) following manu-
facturer’s instructions.
Log Neutralization Index (LNI)
The neutralizing ability of purified IgG from human sera was measured by a constant anti-
body-varying virus plaque-reduction neutralization test [28]. Briefly, BHK-21 cell monolayers
were prepared in 24 well tissue culture plates with 1 ml of cells at a concentration of 2 x 105
cells/ml in RPMI-1640 (Invitrogen, MA, USA) containing 2% heat-inactivated FBS. DENV
serotypes 1–4 with a working stock of approximately 106 PFU/ml were diluted ten-fold (10−1
to 10−6) in RPMI-1640 containing 2% heat-inactivated FBS. A concentration of 10 μg/ml of
purified human IgG was diluted in RPMI-1640 containing 2% heat-inactivated FBS and 100 μl
was mixed with an equal volume of serially diluted viral suspensions in a 96 well round bottom
plate. For a negative control, 100 μl of RPMI 1640 was mixed with equal volume of viral
suspension.
Following incubation at 37°C with 5% CO2 for 2 hours, the virus-antibody mixture was
added in duplicate to the monolayers of confluent BHK-21 cells and incubated at 37°C with 5%
CO2 for 1 hour to allow the virus to absorb to the cells. The wells were then overlaid with 1 ml
of 1.5% CMC (Sigma-Aldrich, MO, USA) and RPMI-1640 containing 2% heat-inactivated
FBS. The plates were incubated at 37°C with 5% CO2 for 4–5 days. After incubation, the cells
were fixed with 3.7% formaldehyde (Sigma-Aldrich, MO, USA), permeabilised with 0.1% Non-
idet P40 (Sigma-Aldrich, MO, USA) and blocked with 2% w/v skimmed milk (Nestle, WA,
Australia). The monoclonal antibody 4G2 was used to label the infected cells and was visual-
ized using horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG (Sigma-Aldrich,
MO, USA). The viral foci were counted and the virus titre was recorded as FFU/ml. Virus neu-
tralization was indicated by the reduction in virus titre following the addition of purified IgG
to virus culture. Neutralization was expressed as a Log Neutralization Index (LNI).
Focus reduction neutralization test (FRNT)
The neutralizing antibody titres of immune mice sera were determined by FRNT as previously
described [30]. Pooled pre-immunization or post-immunization mice sera were heat-inacti-
vated at 56°C for 30 min and diluted 1:10 with RPMI-1640 containing 2% heat-inactivated
FBS. Serial two-fold dilutions of this inactivated mice sera were prepared and 100 μl of the dilu-
tions were mixed with an equal volume of virus suspension containing 50 FFU (focus forming
units) per well. Following incubation at 37°C for 2 hours, the virus-antibody mixture was
added in duplicate to the monolayers of confluent BHK-21 cells and incubated at 37°C with 5%
CO2 for 2 hour to allow the virus to absorb to the cells. The wells were then overlaid with 1.5%
w/v CMC (Sigma-Aldrich, MO, USA) and incubated for 4–5 days. After incubation, the cells
were fixed with 3.7% formaldehyde (Sigma-Aldrich, MO, USA), permeabilised with 0.1% Non-
idet P40 (Sigma-Aldrich, MO, USA) and blocked with 2% w/v skimmed milk (Nestle, WA,
Australia). The monoclonal antibody 4G2 was used to label the infected cells and was visual-
ized using horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG (Sigma-Aldrich,
MO, USA). The neutralizing antibody titer was calculated as the reciprocal of the highest
serum dilution that produced a 50% reduction of 50 focus forming units compared to control
containing the virus and pre-immunization sera [31].
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Enzyme Linked Immunosorbent Assay (ELISA)
Antibody titres were determined by ELISA as described previously [32]. Briefly, ELISA plates
were coated overnight at room temperature with 10 μg/ml of peptides or 5 μg/ml of DENV
recombinant E proteins (Hawaii biotech, USA). Wells were blocked with 50 μl of purified IgG
diluted to 20 μg/ml. For individual or pooled mice sera, serial half-log dilutions were prepared
and 50 μl were added to each well. The plates were incubated for 1 hour and the sera or purified
IgG dilutions were removed and the wells were washed twice. An aliquot of 50 μl (1:1000 dilu-
tion) of HRP-conjugated goat anti-human IgG (Sigma-Aldrich, MO, USA) or HRP-conjugated
rabbit anti-mouse IgG (Sigma-Aldrich, MO, USA) was added. The optical density (OD) of
individual wells was read by an iMark Microplate Reader (BioRad Laboratories, Hercules, CA,
USA) at a wavelength of 450nm. Antibody titres were expressed as the reciprocal of the loga-
rithm of that dilution of serum that gave an OD four times above that obtained in wells with
pre-immune control sera.
Epitope extraction
The extraction of bound peptides to purified human IgG was carried out as described previ-
ously by Grollo et al. (2006). A total of 70 peptides spanning the sequence of the E protein were
arranged into 14 groups containing 5 peptides each at a concentration of 0.2 mg/ml in PBS.
None of the 5 peptides in a group had the same molecular mass and care was taken to make
sure that there was minimal or no peptide sequence overlaps in each group. To 50 μl of each
peptide pool, 50 μl of purified IgG (50 μg) from either dengue patients or non-infected controls
was added and allowed to react for 30 min at room temperature. The peptide-antibody mixture
was then added to compact reaction columns (CRC’s) (USB, Cleveland, OH, USA) containing
50 μg of Protein A-sepharose beads in 50 μl of 50mM Tris-HCl (pH 7.4) and incubated for 30
min at room temperature. The unbound peptides were washed once with washing buffer con-
taining 50mM Tris-HCl (pH7.4) in 0.5M NaCl and 0.5% N-octyl-D-glucoside (Calbiochem,
San Diego, USA) and the peptides bound to the antibody were eluted from Protein-A sephar-
ose beads by addition of 50 μl of elution buffer (0.5% formic acid, Fluka, Buchs, Switzerland).
Mass spectrometry
The eluted peptides were analysed in a Bruker microFLEX (Bruker Daltonics, Germany)
matrix-assisted laser desorption time-of-flight mass spectrometer (MALDI-TOF). Briefly, 1 μl
of eluted peptide was dried on a MALDI sample stage (Bruker Daltonics, Germany) with 1 μl
of MALDI matrix containing α-cyano-4-hydroxycinnamic acid (Sigma-Aldrich, MO, USA) in
50% acetonitrile (Sigma-Aldrich, MO, USA) and 0.1% Tri-fluro acetic acid (Sigma-Aldrich,
MO, USA). Detection was performed in positive reflector mode with m/z range of 1500–3500
using the flexControl software (version 3.0, Bruker Daltonics. Germany). Peak lists were gener-
ated by the flexAnalysis software (version 3.0, Bruker Daltonics, Germany) using the Snap
peak detection algorithm with default settings. Peptides were also identified using LC-ESI-MS/
MS. An aliquot of 10 μl of the eluted peptides were loaded in glass vials (Waters, MA, USA)
and separated by Agilent 1100 series nanoLC (Agilent Technologies, Palo Alto, CA, USA) on a
5 μm (150 mm x 75 μm) Zorbax 300SB-C18 (Agilent Technologies, Palo Alto, CA, USA) chip
column using ChipCube interfaced at the front end of a LC/MSD Trap XCTplus 3D iontrap
mass spectrometer (Agilent Technologies, Palo Alto, CA, USA). Solvent in the mobile phase A
consisted of 0.1% formic acid (Fluka, Buchs, Switzerland) in water and mobile phase B con-
sisted of 95% acetonitrile (Sigma-Aldrich, MO, USA) with 0.1% formic acid (Fluka, Buchs,
Switzerland). The elution gradient for the chip column was from 15% to 50% buffer B over 19
minutes. The mass spectrometer was operated with electrospray ionisation in the positive ion
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mode with m/z range of 1500–3500. Data was acquired using the 6300 Series ion Trap LC/MS
Software 6.1 (Agilent Technologies, Palo Alto, CA, USA). Selected ions were subject to further
MS-MS analysis to confirm peptide identity.
Alternatively, 15 μl of the eluted peptides were loaded onto a 300 μm x 5 mm Zorbax
300SB-C18 (Agilent Technologies, Palo Alto, CA, USA) reversed-phase precolumn attached to
a Shimadzu Prominence nano LC system (Shimadzu Corporation, Kyoto, Japan). The precol-
umn was washed with 0.1% formic acid in 5% acetonitrile for 15 min before placing in-line
with a 150 mm x 75 μm Zorbax 300SB-C18 (Agilent Technologies, Palo Alto, CA, USA)
reversed-phase column. Peptides were eluted using a gradient of 5–65% (v/v) acetonitrile in
0.1% formic acid over 60 min, at a flow rate of 0.25 μl/min. Peptides were analyzed via electro-
spray ionization on a QSTAR Elite hybrid quadrupole time-of-flight (QqTOF) mass spectrom-
eter (Applied Biosystems/MDS Sciex, Foster City, CA, USA). The mass spectrometer was
operated in the positive ion mode with ion source voltage of 2,200 V. Analyst QS 2.0 software
(Applied Biosystems/MDS Sciex, Foster City, CA, USA) was used to collect data in a data-
dependent acquisition mode for the three most intense ions fulfilling the following criteria: m/z
between 450 and 2,000; ion intensity 40 counts; and charge state between +2 and +3. After MS/
MS analysis, these ions were dynamically excluded for 18 s, using a mass tolerance of 50 mDa.
MS scans were accumulated for 0.5 s, and MS/MS scans were collected in automatic accumula-
tion mode for a maximum of 2 s.
Database search
The peptide mass fingerprints (PMFs) fromMALDI-ToF were searched against a local copy of
the non-redundant database SWISS-PROT (http://www.expasy.ch/sprot) using the MASCOT
search program [33]. The MS/MS peak lists in mgf file format (.mgf) from the ion trap were
generated using default parameters in DataAnalysis version 3.4 (Agilent Technologies, Palo
Alto, CA). Peak lists for QSTAR Elite data were made using ProteinPilotTM software version
3.0 (Applied Biosystems/MDS Sciex) and searched against the dengue virus database (Swis-
sprot/Uniprot) using the Paragon algorithm [34]. The Paragon algorithm search parameters
were: Sample type: identification; Cys alkylation: none; Digestion: none; Instrument: LTQ;
Search effort: Thorough ID; Detected protein thresh hold:>0.05 (10%). The false positive rate
determined was 0.2%.
in silico epitope prediction
The epitope prediction workflow was carried out according to Kirk et al. (2012). A combined
in silico approach utilizing computational hidden Markov model (HMM), propensity scale
algorithm, and artificial learning was used to identify 15-mer structurally conserved B-cell epi-
topes on the E protein of DENV-2. The epitopes were identified by combining both sequence
(ABCPred, BepiPred) and structure based (epitopia) prediction approaches. The dengue virus
2 sE protein was computationally analysed for hydrophobicity, surface accessibility, solvent
accessibility, polarity and spatial distance orientation relationships. The sequences were
obtained from NCBI Genbank and scored for the key antigenic characteristics against the
BLASTP [35] query algorithm. Multiple publicly available database sets were sorted and
aligned via the ClustalW. Conserved sequences demonstrating homology within the protein
data bank listings PDB ID: lOAN and 1k4r were used to construct and verify the model. The
predicted epitopes were displayed on a three dimensional structure of DENV-2 E protein (PDB
ID-1OAN) using PDB viewer software. Three dimensional structural model was generated
based on the structural conservation (more than 40%) with the PDB model using the Chimera
[36] interface to modeler [37]. The rate of amino acid substitutions in the alignment of
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homologous proteins was estimated with the help of epitopia server having the reconstructed
crystallographic atomic co-ordinates.
Synthesis of peptide vaccine constructs
Seven vaccine constructs were designed consisting of B cell epitopes selected from our screen-
ing strategies. The B cell epitopes consisted of linear 18-mer synthetic peptides denoted as B2,
B16, B29, B38, B45, B64 and B19. Individual linear peptides were co-synthesized with a helper
T-cell epitope representing the amino acids 352- LITVNPIVTEKDSPVNIE-368 of the DENV-
2 E protein (Jamaica strain). All the vaccine constructs were synthesized by attaching the T-
helper epitope to the amino- terminal end of the B-cell epitope. This TH–cell epitope has previ-
ously been reported to enhance the antibody response to flavivirus B-cell epitopes in BALB/c
mice [38].
Mice immunization
Male 6–8 week old BALB/c mice (5 animals per group) were obtained from the Animal Facility,
Department of Microbiology and Immunology, the University of Melbourne. The animal facil-
ity personnel monitored the animals daily, checking for levels of food and water in each cage.
Mice were also physically checked twice weekly by the researcher. The peptide immunogen
(50μg) was suspended in PBS and emulsified in a 1:1 ratio of complete Freund’s adjuvant
(Sigma-Aldrich, MO, USA) for the first priming dose or incomplete Freund’s adjuvant (Sigma-
Aldrich, MO, USA) for the booster dose. The animals were injected subcutaneously at the base
of the tail with the vaccines in 100uL of solution. The mice were inoculated with vaccine con-
struct on day 0 (primary dose) and the booster dose was administered on day 28. The Animal
house personnel oversee the basic animal maintenance including housing the animals in cages,
a palatable diet, water and bedding. A time-controlled lighting system was used to ensure a reg-
ular diurnal light cycle. The cages were cleaned and sanitised on regular basis. A protocol was
in place for early/humane endpoint if animals became severely ill prior to experimental end-
point. Humane endpoints were defined as follows: If a mouse showed signs of ill health such as
weight loss (greater than 20% of body weight), hunching, ruffled fur or lethargy, it will be
euthanized. The researcher were to be notified immediately if the facility personnel detected
mice that appear unwell. This was recorded in the diary provided. The researcher was then
asked to inspect the animal and euthanize if necessary. However, none of the animals died
prior to experimental endpoint and did not meet the criteria for euthanasia. We also had a pro-
tocol in place to alleviate animal suffering if needed by anesthesia. Following anesthesia, mice
were monitored until they regained consciousness, at which point they were returned to their
cages. The animals were bled on day 0, 10 and 38. Following the final bleed on day 38, the ani-
mals were euthanized by CO2 asphyxiation for 2–3 minutes in a CO2 chamber. Sera was centri-
fuged and the plasma was stored at -20°C until further use.
Statistical analysis
Statistical analysis of all data were performed with GraphPad Prism 5 software (GraphPad Soft-
ware, San Diego, CA, USA). Data derived from at least two independent assays are presented
as mean ± standard error of the mean (SEM). A P value of<0.05 was considered statistically
significant for all parameters and the confidence interval (CI) was 95%. Mean LNI’s were com-
pared to detect significant differences between antibody titres to viruses using one-way analysis
of variance (ANOVA) followed by the Bonferroni multiple comparison test. The statistical
analyses of the mice antibody titres were carried out using two-tailed Student’s t–test and each
of the resultant P values for a particular comparison is shown in the appropriate text or in the
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figure legend. Mean FRNT50 values were compared by one-way ANOVA followed by Tukey’s
honestly significant difference (HSD) multiple comparison test with significance level alpha
(P) set at 0.05.
Results
Identification of peptide-antibody binding through ELISA
Sera collected from dengue positive human subjects were screened against 18-mer synthetic
peptides representing the DENV-2 E protein through direct binding ELISA (S2 Table). Of the
total 70 peptides being screened, 17 peptides showed high reactivity towards the DENV-2
human polyclonal IgG. The IgG from four DENV negative individuals was used as a control
and the mean absorbance of negative control plus 3 times the standard deviation (OD-0.128)
was used as the cut-off line to identify the positive IgG reactive peptides.
The relative position of the 17 peptides representing the DENV-2 E protein is shown in Fig
1. The peptides were distributed in several regions across the entire E protein of DENV-2 at
amino acid positions 8–25, 106–123, 127–144, 190–207, 225–242, 260–291, 295–347, 365–389,
442–459 and 470–495. Peptides 2 and 16 were found within the EDI and EDII of sE, respec-
tively. Peptide 19, corresponding to aa 127–144, is located within the “hinge” region between
EDI and EDII, and previous studies have shown that the partial sequence (aa 127–134) of pep-
tide 19 is an immunodominant epitope [39]. The P40 peptide (aa 274–291) was located within
the “hinge” region between EDI and EDIII, and the epitope interacting with the fusion loop
reactive monoclonal antibody MAb 4G2 has been reported to be harbored in this region. MAb
4G2 is highly conformational and broadly cross-reactive to all four DENV serotypes [40].
The region corresponding to amino acids 295–347 (represented by peptides 43, 45, 47 and
48) and aa 365–389 (represented by peptide 53 and 54) are located within the EDIII domain of
the sE protein. Apart from epitopes present on the soluble E protein, four peptides were
Fig 1. Synthetic peptides of the DENV-2 E-glycoprotein binding with IgG in ELISA. The position of the 17 peptides (18-mers)
recognized by the immune sera in ELISA is shown as grey bars. The soluble E protein (residues 1–395) comprising domains I, II, and III
are coloured in red, yellow, and blue, respectively. The peptide sequences for each of the synthetic peptides are shown.
doi:10.1371/journal.pone.0155900.g001
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identified in two different antigenic regions representing the membrane proximal “stem”
region of the E ectodomain corresponding to aa 442–459 (represented by peptide 64) and aa
470–495 (represented by peptides 68, 69 and 70).
Epitope extraction
The synthetic peptides were grouped into 14 pools with each pool comprising 5 peptides.
These peptides were allowed to react with purified IgG in solution at neutral pH. The subse-
quent mass spectrometry of the reactive peptides showed 21 peptides able to bind to the
DENV-2 positive IgG (S3 Table), whereas IgG from DENV negative human sera did not show
reactivity towards these peptides. Since we used an overlapping peptide library with 11 amino
acid overlaps at both ends, we selected the positively reacted peptides based on the reaction pat-
tern. For example, since the peptides 1, 2 and 3 all reacted positive, we selected peptide 2 for
animal studies as it represents 11 amino acids of peptide 1 and 3. This selection criterion was
carried out in order to advance the peptides to animal studies.
For example, peptide 2 (NRDFVEGVSGGSWVDIVL) corresponding to aa 8–25 of the E
protein (EDI) reacted with most immune IgGs tested. Mass spectrometry showed the corre-
sponding m/z value of 1949 with possible b and y ion coverage both as single and/or doubly
charged ion (Fig 2). We have shown the chromatogram of peptide 2 as an example representa-
tion of mass-spectrometry studies. A similar pattern of antibody reaction against all IgGs was
observed with peptide 16 (106-GLFGKGGIVTCAMFTCKK-123), with a m/z value of 1861
and peptide 45 (309-VKEIAETQHGTIVIRVQY-326), with a m/z value of 2084. The immuno-
dominant peptide 19 located in the “hinge” region between EDI and EDII
Fig 2. Mass spectrum of peptide 2 identified throughMALDI-ToFmass spectrometry corresponding to m/z 1949.
Pools of overlapping peptides (18-mers, n = 5) spanning the entire E protein of DENV-2 were assembled such that no pool
contained peptides of similar mass. These peptide pools were allowed to react with IgG purified from DENV-2 infected
patient’s sera and the antibody-bound peptides were extracted in acidic conditions. Following extraction, one peptide with a
m/z value of 1949 was identified through MALDI-ToF mass spectrometry. MS/MS sequencing of peptide ion mass 1949
unequivocally defines it as deriving from peptide 2 sequence (NRDFVEGVSGGSWVDIVL) with the b and y ion coverage
shown in the table.
doi:10.1371/journal.pone.0155900.g002
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(127-GKVVLPENLEYTIVITPH-144) and peptide 64 representing the membrane proximal
“stem” region (442-AIYGAAFSGVSWTMKILI-459) of the E protein also showed a positive
reaction against antibodies in solution with a m/z value of 2022 and 1928, respectively. In con-
trast to ELISA which showed non-binding to IgG, peptides 29 (197-VLLQMEEKAWLVH
RQWFL-214) and 38 (260-MHTALTGATEIQMSSGNL-277) showed an ability to bind to 14
IgGs present in clinical samples when tested using the epitope extraction approach.
in silico B-cell epitope prediction
Amulti-step computational approach was used to identify the linear B-cell epitopes from the
DENV-2 E protein based on surface accessibility of residues, hydrophobicity and the spatial
distance orientation relationship [26]. The potential linear epitopes identified through the
computational approach were shown as 14-mer amino acid sequences. A score of> 0.65 was
considered as the cut off level for selecting positive epitopes. There were 16 B-cell epitopes
identified on the E protein of DENV-2 (Table 1). The epitopes identified on DENV-2 E protein
were categorized into 6 distinct antigenic regions. Epitopes found in greater spatial proximities
were discounted as their normal position lay buried and potentially limiting exposure of the
epitope on the surface. All predicted sequences of the B-cell epitopes were screened to deter-
mine if they shared any sequence similarity with human proteins and none was found to be
homologous with the human proteome, thus confirming that there would be no occurrence of
auto-immune reactions. Areas that are shaded in red indicate the most conserved, and most
likely immunogenic based on the physiochemical properties of amino acids and their corre-
sponding stereochemistry. Exposed and likely immunogenic regions are clustered around the
underside of the canyon of this predicted model and shaded in light pink. Regions that are not
considered immunogenic are shown in blue (Fig 3).
Table 1. Epitopes identified on the DENV-2 E protein.
Regions Epitope sequence Position on E protein Score
1 RCIGISNRDFVEGV 2–1 0.89
GISNRDFVEGVSGG 55–18 0.85
2 DRGWGNGCGLFGKG 98–111 0.80
GLFGKGGIVTCAMF 106–119 0.75
KGGIVTCAMFTCKK 110–123 0.69
3 EGKIVQPENLEYTI 126–139 0.82
PENLEYTIVITPHS 132–145 0.81
4 FNEMVLLQMENKAW 193–206 0.84
LQMENKAWLVHRQW 199–213 0.70
LDLPLPWLPGADTQ 214–227 0.70
5 GSQEGAMHTALTGA 254–267 0.68
TALTGATEIQMSSG 262–275 0.73
6 SYSMCTGKFKVVKE 298–311 0.81
KVVKEIAETQHGTI 307–320 0.78
AETQHGTIVVRVQY 313–326 0.77
IVVRVQYEGDGSPC 320–333 0.80
The potential linear epitopes identiﬁed through the computational approach were shown as 14-mer amino acid sequences. A score of > 0.65 was
considered as the cut off level for selecting positive epitopes.
doi:10.1371/journal.pone.0155900.t001
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Immunogenicity of predicted B-cell epitopes
A total of 7 B-cell epitopes (B2, B16, B29, B38, B45, B64 and B19) were evaluated as vaccine
candidates as these epitopes were identified through a combination of three epitope mapping
strategies (Table 2). The location of 6 of these epitopes is displayed on the 3-dimensional struc-
ture of the DENV-2 E protein (PDB ID- LOAN) (Fig 4). The T-helper epitopes were attached
to the amino- terminal of the B-cell epitope. The resulting vaccine construct was used to inocu-
late the mice on day 0 (primary dose), and the booster dose was administered on day 28. The
animals were bled on days 0, 10 and 38. The immune sera were used to determine the anti-pep-
tide antibody response in ELISA using the corresponding 18-mer native B-cell epitope as the
antigen. The antibody response of individual mouse within a group and the mean antibody
titre of each vaccine construct are shown in Fig 5. Following the secondary booster dose, the
peptides B16, B29, B45, B64 and B19 elicited significant anti-peptide antibody titres (P<0.05)
when compared to the primary dose. Though the antibody titres elicited by these five peptides
following secondary booster were not significantly different, the highest mean titre was
observed in mice sera elicited by the vaccine construct B19 (log10 2.918) followed by B16 (log10
2.697). There was no statistically significant reduction observed in binding efficacy between
specific antibodies to the conjugate peptide (T-helper and B-cell epitope) when compared to
the native 18-mer B- cell peptide (S1 Fig).
Sera from all five mice within a group were pooled and the resulting immune sera were used
to test the cross-reactive antibody response in ELISA against soluble E (sE) recombinant pro-
tein of DENV-1 (395 aa), DENV-2 (395 aa) and DENV-3 (393 aa). The log10 antibody titre of
six vaccine constructs, B16, B29, B38, B45, B64 and B19, are shown in Fig 6. The construct B2
did not elicit an antibody response to any of the recombinant proteins. All six sera reacted with
the DENV-2 recombinant protein. The anti-peptide antibodies were observed to differ widely
in their cross-reactivity. The antisera elicited by the vaccine constructs B16, B29 and B45
showed cross-reactivity against all three DENV recombinant proteins (DENV-1, 2 and 3). In
Fig 3. Immunogenicity of DENV E protein (PDB id: 1k4r) super imposed with Bayesian Predictive
Algorithm. Top view of the homology model of DENV E protein monomer, PDB id- 1k4r is shown with amino
acid residues indicated in space filling model. Colour coded regions correspond to epitopes predicted to have
neutralizing ability. Areas shaded in red are indicative of most conserved, surface exposed residues and
most likely immunogenic. Areas shaded in light pink are exposed and likely immunogenic, where as those in
blue are considered least conserved and not immunogenic.
doi:10.1371/journal.pone.0155900.g003
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particular, the levels of immunoglobulins elicited against the conserved E protein fusion loop
represented by construct B16 showed the highest antibody titre and were broadly cross-reactive
against DENV-1, DENV-2 and DENV-3 recombinant proteins with log10 titres of 4.000, 4.215
and 4.05, respectively. In contrast, three constructs elicited only a homologous antibody
response against DENV-2; these were constructs B19 (log10 3.691), B64 (log10 2.975) and B38
(log10 2.025).
Neutralizing activity of anti-peptide antibodies in vitro
Pooled immune sera at various dilutions were used to test the neutralizing activity against
DENV-1, DENV-2, DENV-3 and DENV-4 in an in vitro focus reduction neutralization assay
(FRNT) using BHK-21 cells (Fig 7). The sera dilution which caused a 50% reduction of focus,
when compared to the pre-immune serum/saline-adjuvant serum control, was considered to
be the end-point titre (FRNT50). Homologous neutralizing antibody response against DENV-2
was observed in vaccine constructs B16, B38 and B19 with neutralizing antibody titres
(FRNT50) of 1:80, 1:10 and 1:40, respectively. The vaccine constructs B29 and B45 showed a
heterotypic neutralizing antibody response against both DENV-2 and DENV-3. The 50% neu-
tralizing antibody titres of B29 were 1:80 (DENV-2) and 1:10 (DENV-3), whereas the antibody
titres elicited by the B45 vaccine construct against DENV-2 and DENV-3 were 1:80 and 1:20,
Fig 4. Location of epitopes on the DENV-2 protein. Top view of the dimeric form of the DENV-2 E protein
residues 1–395 (PDB ID-LOAN). The domains I, II and III are coloured red, yellow and blue, respectively. The
epitopes identified from 3 different epitope mapping strategies were coloured in green. A) e pitope B2, B)
epitope B16, C) epitope B19, D) epitope B29, E) epitope B38, F) epitope B45.
doi:10.1371/journal.pone.0155900.g004
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respectively. The pooled sera from the construct B2 did not elicit a neutralizing antibody
response against any of the four DENV serotypes indicating that the antibodies elicited by con-
struct B2 were binding but lacking neutralizing activity. In contrast, the vaccine construct
derived from the E ectodomain region represented by B64 elicited a neutralizing antibody
response against both DENV-1 and DENV-2 (Fig 6E), with FRNT50 titres of 1:10 and 1:80,
respectively.
Discussion
Dengue poses a significant public health threat and currently, no vaccine or antiviral therapy
are available. The phase III clinical trials of Sanofi Pasteur tetravalent chimeric yellow-fever
dengue vaccine (Dengvaxia1) in Asia (Indonesia, Malaysia, Philippines, Thailand, Vietnam)
[13] and the Latin America (Brazil, Colombia, Honduras, Mexico, Puerto Rico) [14] showed
the overall vaccine efficacies as 56.5% and 64.7%, respectively. However, the serotype-specific
vaccine efficacy in Asia was substantially lower at 50% for serotype 1 and 35% for serotype 2
[13]. Similar trend in serotype-specific vaccine efficacy was also reported in the Latin American
phase III clinical trial where the efficacies were 50.3% for serotype 1 and 42.3% for serotype 2
[14]. The predominant serotypes circulating in the South East Asian region were reported to be
serotype 1 and 2 [41]. Clearly, alternative strategies are needed for the dengue vaccine develop-
ment pipeline.
Fig 5. Immunogenicity of peptide vaccines B2, B16, B29, B38, B45, B64 and B19 coupled to a helper T-
cell epitope. For primary (open circles) inoculation, groups of BALB/c mice (n = 5) were administered
subcutaneously with 50 μg of the peptide immunogen in complete Freund’s adjuvant (CFA) on day 0 (1°).
Negative control animal groups received CFA and saline. The secondary (closed circles) booster dose was
administered subcutaneously on day 28 (2°) with 50 μg of the peptide immunogen in incomplete Freund’s
adjuvant (IFA). Mice were bled on days 0, 10 and 38, and sera obtained. ELISA was performed using 18-mer
synthetic peptide representing each of the 7 peptides as the antigen coated overnight on 96 well plates.
Antibody titres are expressed as the reciprocal of the logarithm of that dilution of serum that gave an optical
density four times above that obtained in wells with pre-immune control sera. Individual animal titres are
presented with the mean value represented by the horizontal bar and p values are indicated between the
primary and secondary dose.
doi:10.1371/journal.pone.0155900.g005
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Fig 6. Cross-reactive binding response of anti-peptide antibody against the sE recombinant protein of DENV-1,
DENV-2 and DENV-3. Sera raised against each peptide group were pooled (n = 5) and the resulting immune sera were
used to test the cross-reactive antibody response in ELISA. The log10 antibody titres raised against each vaccine
construct (B16, B29, B38, B45, B64 and B19) were evaluated using the recombinant E protein of DENV-1 (clear bar),
DENV-2 (dark bar) and DENV-3 (shaded bar).
doi:10.1371/journal.pone.0155900.g006
Fig 7. Neutralizing activity of anti-peptide antibodies against four DENV serotypes. Serially diluted pooled immune sera
from vaccine constructs B16, B29, B38, B45, B64 and B19 were used to test the virus neutralizing activity against DENV-1,
DENV-2, DENV-3 and DENV-4 in an in vitro focus reduction neutralization assay (FRNT) employing BHK-21 cells. A dilution
resulting in 50% reduction of focus when compared to the pre-immune serum was considered as the end-point titre (FRNT50).
Each neutralization curve is an average (±S.E.M) of two independent neutralization experiments with a pooled serum group.
doi:10.1371/journal.pone.0155900.g007
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Peptide vaccines containing specific epitopes capable of inducing humoral and cellular
immune responses are considered to be an alternative strategy [19]. These peptide vaccines can
be used for induction of broad-spectrum immunity against multiple strains while eliminating
allergenic and/or reactogenic complications [42]. Rocha et al. (2014) reported that the tetrava-
lent peptide vaccines derived from the highly conserved region on the dengue E protein elicited
antibodies but they showed low neutralizing activity (PRNT50<1:20) and failed to neutralize
all 4 serotypes. A possible strategy is that the peptide vaccine constructs can be designed with
selected epitopes from the four dengue serotypes [16].
Since DENV serotype 2 and 3 are predominant in Australia, we focused on identifying a B-
cell epitope which could elicit cross-reactive neutralizing antibodies against serotypes 2 and 3.
Three different epitope mapping strategies were used to identify potential B-cell epitopes on
the E protein from dengue virus serotype 2. The soluble E-glycoprotein has three structural
domains: EDI (residues 1–52, 132–182 and 280–295), EDII (residues 53–131 and 193–279)
and EDIII (residues 303–395) [3]. From the 17 peptides which showed positive binding to IgG
by ELISA, those representing amino acid position 106–123 (peptide 16), 197–214 (peptide 29),
225–242 (peptide 33) and 260–277 (peptide 38) are located on EDII and those representing
amino acids 295–312 (peptide 43), 309–326 (peptide 45), 323–340 (peptide 47), 330–347 (pep-
tide 48), 365–382 (peptide 53) and 372–389 (peptide 54) are located on EDIII. On the other
hand, the solution phase epitope extraction technique revealed 21 peptides that were bound by
the immune IgG, of which 9 (peptides 2, 16, 19, 29, 33, 38, 40, 45 and 64) were also identified
to be positive in ELISA. These in-solution reactions were useful to maintain the conformational
integrity required for some of the peptides to be able to bind to the antibody [25, 43].
A combination of both ELISA and epitope extraction approaches are useful in epitope map-
ping as these techniques together could enhance the number of epitopes identified. For exam-
ple, peptides 43, 47, 48, 53, 54, 68, 69 and 70 reacted positively in ELISA only. In contrast,
peptides 1, 3, 20, 30, 32, 37, 39, 52, 62, 63, 65 and 66 were identified only in epitope extraction
approach. Inclusion of both these mapping strategies could enhance the epitope repertoire
when combined together. For instance, peptides 29 and 38 showed mild reactivity against the
IgG samples in ELISA whereas; in-solution epitope extraction revealed that these two peptides
were able to bind well to several IgG samples. Moreover, peptides 68, 69 and 70 showed posi-
tive reactions in ELISA, but did not bind to the antibody in solution. Similar binding reactions
in ELISA were seen in DENV-2 trans-membrane domain using murine MAbs [44].
The multi-step in silico B-cell epitope prediction approach identified 6 potential antigenic
regions on the E protein of DENV-2. These regions encode 16 epitopes predicted to be poten-
tial B-cell epitopes. Of 16, two epitopes were not reacted positive in both experimental
approaches (aa position 214- LDLPLPWLPGADTQ -227 and 298- SYSMCTGKFKVVKE
-311). In addition, a truncated peptide at position 98-DRGWGNGCG -106 was also predicted.
Previous computational approaches to identify the epitopes on DENVmostly used a single
algorithm to predict the epitopes [17, 22]. Furthermore, most of the predictive epitope data
training sets contain data entry ambiguities or error prone alignments with high degree of simi-
larity with other peptide sequences reported within the same data set [26]. Peptides were
excluded if they shared sequence homology with human proteins which could induce a delete-
rious response.
A combination of the three strategies revealed a total of 6 novel peptides (peptides 2, 16, 29,
38, 45 and 64) that could serve as B-cell epitopes. The ELISA and epitope extraction methods
are high throughput, cost effective and less time consuming such that the antibody binding
potential of synthetic peptides can be rapidly screened. However, when compared to ELISA,
the epitope extraction technique requires additional sample preparation steps and technical
expertise to perform the peptide identification through mass spectrometry. The computational
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epitope prediction is quick with epitopes identified using a combination of several predictive
algorithms [19]. Hence, these three strategies when combined will be useful for fine epitope
mapping of DENV and other related flaviviruses.
Peptide-based vaccines are often poorly immunogenic and require adjuvants and effective
delivery systems to improve the immunostimulatory properties. Emulsion based delivery
methods are highly adopted in vaccine studies, of which Freund’s complete adjuvant (CFA)
and Freund’s incomplete adjuvant (IFA) are most popular [45]. In addition, linear B-cell epi-
topes are limited in their potential to elicit a strong antibody response as it is challenging to
mimic the conformation of native protein [46] and also a lack of helper T-cell response. Using
synthetic peptides to induce adequate mature B-cell memory responses often requires cyto-
kines from T-helper (TH) cells, and induction of robust helper T-cell response is crucial [47].
Hence when selecting epitopes for B-cell mediated vaccine strategy, we must also focus on
induction of helper T-cell responses. T-cell help can be provided through co-synthesizing lin-
ear helper T-cell epitopes along with the B-cell epitopes [26].
The 6 peptides identified in this study as potential B-cell epitopes were synthesized along
with a TH–cell epitope and these vaccine constructs (B2, B16, B29, B38, B45 and B64) were
evaluated in inbred BALB/c mice. Peptide 19 was previously shown to recognize anti-dengue
sera [39] and we included peptide 19 as a positive control. The vaccine constructs B29 and B45
elicited strong neutralizing response against DENV-2 and a low cross-neutralizing activity
against DENV-3. Antibodies elicited by both constructs were able to bind to the E recombinant
protein of DENV-1 but was unable to neutralize the DENV-1 serotype. The peptide B29 is
located within the EDII domain and nine amino acids were conserved between position
204-KAWLVHRQWF-213 in both DENV-2 and -3. The computational analysis of this region
has revealed the highly accessible nature on the surface of the E protein of DENV-2. The EDIII
domain has been reported to elicit strong neutralizing response against multiple DENV sero-
types [8, 48], and the peptide B45 was located within this domain. In addition to high homoty-
pic neutralizing activity against DENV-2, the construct B-45 elicited heterotypic antibodies
that could cross-neutralise DENV-3. Both DENV-2 and -3 serotypes exhibit 10 conserved
amino acids between positions 314-ETQHGTIVIRVQY-326. EDIII connects to a stem region
and the transmembrane (TM) domain with several epitopes been reported to induce cross-
reactive neutralising response [7, 49, 50].
Previous studies have shown that the majority of sequences in the “stem” region were con-
served across all DENV serotypes [51] and the epitope B64 representing the “stem” anchor
region located at aa 442–459 had 11 conserved amino acids in positions
448-FSGVSWTMKILI-459 between DENV-1 and DENV-2. The computational analysis has
revealed that the B64 epitope region is moderately accessible on the surface of the virion parti-
cle. The antibodies elicited by B64 were able to neutralize DENV-2 with FRNT50 titre 1:80 and
DENV-1 at 1:10. Surprisingly, these antibodies reacted against the DENV-2 soluble recombi-
nant protein but did not cross-react with DENV-1. Since the linear amino acid sequence of
peptide B64 does not represent any epitope region on the sE protein, the antibody might have
bound to a conformational epitope present on DENV-2 but not in other serotypes. This is yet
another interesting observation as recent studies have shown that depletion of sE binding
human antibodies have minor impact on DENV neutralising ability [52]. In addition, antibod-
ies recognizing multiple domains on the surface of the virion have also been reported [53].
Peptide vaccines are reported to have low immunogenicity when compared to a whole virus
or recombinant protein vaccine construct. Low doses of the recombinant truncated E proteins
(r80E) of four DENV serotypes manufactured by Hawaii Biotech Inc., HI, USA were shown to
induce complete protection in mice and monkeys as measured by PRNT [54]. However, sub-
unit vaccines require bulk culture reactors and purification facilities which questions the cost-
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effectiveness. Walter Reed Army Institute of Research (WRAIR), Maryland, USA, in collabora-
tion with GlaxoSmithKline Biologicals has evaluated the efficacy of purified inactivated dengue
vaccine (PIV) in mice and Rhesus macaques. The candidate tetravalent dengue vaccine formu-
lated with alum or an adjuvant system (AS01, AS03 or AS04) induced robust neutralising anti-
body titers against all four dengue serotypes [55]. Although inactivated vaccines are free from
disadvantages such as reversion to a pathogenic phenotype, they require purification processes
for removal of the formaldehyde which may lead to conformation changes of the virion. In
addition, due to the need to incorporate four serotypes in the inactivated vaccine, the virus
antigen of each serotype may not be equally represented in the vaccine formulation and hence
the neutralizing antibodies to each serotype might differ.
Neutralizing antibodies at suboptimal concentrations or pre-existing cross-reactive antibod-
ies in dengue patients are hypothesized to enhance the severity of subsequent DENV infection
through the phenomenon known as “Antibody-dependent enhancement (ADE)” of infection
in monocytes and macrophages through Fcγ receptor mediated endocytosis [56]. Hence, a suc-
cessful vaccine must induce sufficiently high levels of heterologous neutralising antibodies to
protect against dengue infections and also avoid ADE resulting from future infections. Syn-
thetic peptide vaccines is an attractive alternative strategy as they have a number of potential
advantages over conventional vaccines such as (i) the absence of infectious viral material in
vaccine formulations, (ii) easy introduction of lipid, carbohydrate and phosphate groups to
increase the stability and immunogenicity of vaccine constructs, (iii) economical large-scale
production, (iv) ability to store in lyophilized form, eliminating the need for cold-chain, (v) no
risk of reversion or recombination (vi) the ability to include multiple vaccine antigenic peptides
(epitopes) from several different or the same pathogen [57].
In this study, we showed that mice inoculated with synthetic peptides from the dengue 2 E
protein were able to elicit broad neutralising antibodies to either serotypes 1 and 2 (peptide
B64) or 2 and 3 (peptides B29 and B45). These peptides were identified using three different
epitope mapping approaches and they are conserved within different strains of dengue sero-
type 2 but also share amino acids with other serotypes. However, the strong neutralizing effi-
cacy was elicited against dengue serotype 2 only and a weak cross-neutralizing response was
observed to serotypes 1 and 3. A limitation of the study is that whether the anti-peptide anti-
bodies would pose a greater risk of severe dengue in patients than anti-DENV antibodies aris-
ing following a natural infection is unknown. In addition, these peptides may serve as a
platform for a monovalent vaccine formulation and similar epitope mapping approaches are
required to identify epitopes from serotypes 1, 3 and 4 in order to achieve a balanced high neu-
tralizing titre against all four serotypes in a tetravalent vaccine formulation. Such a vaccine for-
mulation might boost the levels of cross-neutralising antibodies to all four serotypes and
combat ADE.
Although the neutralisation titre to the heterologous serotype was lower than the homolo-
gous serotype, it has been shown in an earlier study that human subjects who received a pri-
mary dose of monovalent live attenuated dengue vaccine elicited a strong serotype specific
response and low levels of heterotypic cross-neutralizing antibody response. However, upon
secondary immunization with a heterotypic monovalent vaccine, it was able to elicit high levels
of neutralising antibody response to all four serotypes. In particular, individuals developed
multitypic neutralizing antibodies not only against the exposed serotypes but also against sero-
types to which they have not yet been exposed. These heterotypic antibodies could protect
against multiple DENV serotypes and avoid ADE [58]. Clearly, further investigation is required
to evaluate the ADE effect of the cross-neutralizing epitopes identified in our approach and the
effect of mutations within these epitope sequences.
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A successful vaccine must elicit both humoral and cellular immune responses against all
four serotypes, and protect against the disease even upon multiple infections. The epitopes
identified in our approach in conjunction with other well-documented epitopes of DENV have
implications for future development of epitope-based synthetic dengue vaccines. It is crucial to
develop a tetravalent dengue vaccine that elicits specific neutralizing antibodies against all four
DENV serotypes to overcome the phenomenon of antibody- dependent enhancement associ-
ated with DSS and DHF [1, 10]. Since vaccination with a tetravalent vaccine appears to be a
promising strategy for dengue disease prevention, the combined approaches employed in the
current investigation could be used to evaluate the potential B-cell epitopes against all four
DENV serotypes. These serotype specific epitopes may be combined for the development of a
future tetravalent multi-epitope vaccine comprising selected epitope sequences from all four
dengue serotypes.
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